Anika Therapeutics
ANIK
145 hedge funds and large institutions have $543M invested in Anika Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 53 increasing their positions, 48 reducing their positions, and 33 closing their positions.
2,634% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $762K
10% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 48
2.32% less ownership
Funds ownership: 95.21% → 92.89% (-2.3%)
11% less capital invested
Capital invested by funds: $613M → $543M (-$69.6M)
12% less funds holding
Funds holding: 164 → 145 (-19)
52% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$21.1M |
| 2 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$9.71M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.57M |
| 4 |
BlackRock
New York
|
+$4.13M |
| 5 |
Millennium Management
New York
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$33.1M |
| 2 |
Kayne Anderson Rudnick Investment Management
Los Angeles,
California
|
-$12.3M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$7.06M |
| 4 |
PGM
Parian Global Management
Pound Ridge,
New York
|
-$4.65M |
| 5 |
ZDA
Zweig-DiMenna Associates
New York
|
-$2.77M |
ANIK Hedge Fund Activity: Q1 2021 in Review
145 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q1 2021, worth a combined $543M — down 11% from $613M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of ANIK and 16 opened new positions — a net loss of 17 holders — while 48 trimmed existing stakes and 53 added.
The largest buyer was Morgan Stanley, adding an estimated $21.1M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $33.1M sold.
- 145 institutional investors held Anika Therapeutics (ANIK) as of Q1 2021, down from 164 in Q4 2020.
- Funds reported $543M of Anika Therapeutics stock for Q1 2021, down 11% quarter-over-quarter.
- 16 funds opened new Anika Therapeutics positions in Q1 2021 and 33 closed out, a net change of -17 holders.
- The largest Anika Therapeutics buyer in Q1 2021 was Morgan Stanley, an estimated $21.1M added.
- The largest Anika Therapeutics seller in Q1 2021 was Avidity Partners Management, an estimated $33.1M sold.
Based on aggregated 13F filings for Q1 2021.